Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD)

Archives of Gerontology and Geriatrics

Volumn 57, Issue 3, 2013, Pages 288-291

  Song, In Uk ^a   Kim, Joong Seok ^b   Park, In Seok ^b   Kim, Young Do ^a   Cho, Hyun Ji ^a   Chung, Sung Woo ^a   Lee, Kwang Soo ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Dementia; Hcy; Levodopa; PD

Indexed keywords

HOMOCYSTEINE; LEVODOPA;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL DEMENTIA RATING; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE DURATION; DRUG RESPONSE; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; KOREA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

DEMENTIA; HCY; LEVODOPA; PD;

AGED; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; DEMENTIA; FEMALE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84881665826     PISSN: 01674943     EISSN: 18726976     Source Type: Journal    
DOI: 10.1016/j.archger.2013.04.015     Document Type: Article

References (19)

1. Barone P., Burn D.J., van Laar T., Hsu C., Poewe W., Lane R.M. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Movement Disorders 2008, 23:1532-1540.
2. Bialecka M., Kurzawski M., Roszmann A., Robowski P., Sitek E.J., Honczarenko K., et al. Association of COMT, MTHFR, and SLC19A1 (RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenetics and Genomics 2012, 22:716-724.
3. Camicioli R.M., Bouchard T.P., Somerville M.J. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Movement Disorders 2009, 24:176-182.
4. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurology 2006, 5:235-245.
5. Ford A.H., Almeida O.P. Effect of homocysteine lowering treatment on cognitive function: A systematic review and meta-analysis of randomized controlled trials. Journal of Alzheimer's Disease 2012, 29:133-149.
6. Hoehn M.M., Yahr M.D. Parkinsonism: Onset, progression and mortality. Neurology 1967, 17:427-442.
7. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry 1992, 55:181-184.
8. McCaddon A., Hudson P., Davies G., Hughes A., Williams J.H., Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dementia and Geriatric Cognitive Disorders 2001, 12:309-313.
9. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
10. Muller T. Role of homocysteine in the treatment of Parkinson's disease. Expert Review of Neurotherapeutics 2008, 8:957-967.
11. Muller T., Jugel C., Ehret R., Ebersbach G., Bengel G., Muhlack S., et al. Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel. Journal of Neural Transmission 2011, 118:1329-1333.
12. Padovani A., Costanzi C., Gilberti N., Borroni B. Parkinson's disease and dementia. Neurological Sciences 2006, 27(Suppl. 1):S40-S43.
13. Ramakrishnan S., Sulochana K.N., Lakshmi S., Selvi R., Angayarkanni N. Biochemistry of homocysteine in health and diseases. Indian Journal of Biochemistry and Biophysics 2006, 43:275-283.
14. Rodriguez-Oroz M.C., Lage P.M., Sanchez-Mut J., Lamet I., Pagonabarraga J., Toledo J.B., et al. Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study. Movement Disorders 2009, 24:1437-1444.
15. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New England Journal of Medicine 2002, 346:476-483.
16. Toth C., Breithaupt K., Ge S., Duan Y., Terris J.M., Thiessen A., et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Annals of Neurology 2010, 68:28-36.
17. Wald D.S., Kasturiratne A., Simmonds M. Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participants. Alzheimer's & Dementia 2011, 7:412-417.
18. Zoccolella S., dell'Aquila C., Abruzzese G., Antonini A., Bonuccelli U., Canesi M., et al. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Movement Disorders 2009, 24:1028-1033.
19. Zoccolella S., Lamberti S.V., Iliceto G., Santamato A., Lamberti P., Logroscino G. Hyperhomocysteinemia in l-dopa treated patients with Parkinson's disease: Potential implications in cognitive dysfunction and dementia?. Current Medicinal Chemistry 2010, 17:3253-3261.